Brief: Anthera Pharmaceuticals completes interim analysis from trial with Blisibimod
10/02/2015 13:45
Feb 10 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O : * Announces completion of interim analysis from phase 3 trial with blisibimod for systemic lupus erythematosus * Says enrollment to be completed in 2015 with final data in Q3 2016 * Says enrollment in the trial is projected to conclude in mid-2015 * Source text for Eikon ID:nPnbs6CzG * Further company coverage ANTH.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman